Skip to content

Efficacy of Paste Type Acellular Dermal Matrix(CG Paste) in Chronic Wound Healing

Clinical Trial for the Efficacy and Safety of Paste Type Acellular Dermal Matrix in Chronic Wound Healing

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04019639
Enrollment
90
Registered
2019-07-15
Start date
2017-04-05
Completion date
2020-07-31
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Wound

Keywords

ADM, acellular dermal matrix

Brief summary

The purpose of this study is to evaluate the efficacy and safety of wound sizing and completeness in chronic window treatment, and to confirm the superiority of area reduction in CG Paste and form-dressing as compared to form-dressing alone groups and CG Paste and form-dressing companion groups.

Detailed description

wound refers to a condition in which the skin is damaged by a cause. In general, open wound rather than closed wound requires active treatment. It is important to make sure that the wound are cured early and through proper treatment. If the wound is open for a long time, secondary complications such as infection can occur and are easy to transition to chronic wound. Chronic wound refers to an idea that does not heal after a period of time after a normal wound healing process, which is usually defined as if it does not heal for more than three to four weeks. 1. These chronic wound include diabetic foot ulcer, pressure ulcer, vascular ulcer, etc. In addition, with the recent aging of the population, the proportion of elderly patients increases, and the proportion of chronic wound where even simple surgical wound does not heal normally, resulting in increased expenditure on health care and decreased quality of life for patients. Biotechnical dermal transplantation material, including acellular dermal matrix, are known to be more effective in wound healing than conventional wound treatments. The mechanism of action of acellular matrices including acellular dermal matrix, is as follows: 1) it functions as a support for cell growth and granulation tissue formation, 2) has receptors capable of attaching to fibroblasts, 3) induction of angiogenesis, 4) chemoattractant activity of vascular endothelial cells, 5) role of providing various growth factors, and temporary storage function. Unlike other products generally known as CG paste, the acellular allo-dermal matrix product to be used in this study is made into a paste type for ease of use after freeze-drying and granulation process after undergoing the process of degreasing of the same kind of dermis . Conventional sheet-type products can not be applied to curved wounds, they must be cut and rehydrated during use, while CG paste is easy to apply to curved wounds and can be applied directly to the desired wound area without rehydration It is expected to be a ready-to-use product with similar clinical effects to existing acellular allo-dermal matrix. The purpose of this study is to evaluate the efficacy and safety of wound sizing and completeness in chronic window treatment, and to confirm the superiority of area reduction in CG Paste and form-dressing as compared to form-dressing alone groups and CG Paste and form-dressing companion groups.

Interventions

DEVICEapplication of CG Paste+EasyFoam

Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.

DEVICEapplication of EasyFoam

Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.

Sponsors

Korea Health Industry Development Institute
CollaboratorOTHER_GOV
Hanyang University
CollaboratorOTHER
St Vincent's Hospital
CollaboratorOTHER
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults over 19 years * Patients with skin defect from full-thickness skin defect to bone exposure level after debridement of wound * Chronic wounds that have not been healed despite adequate treatment for more than 3 weeks after wounding * At the time of the study, patients with a wound size of 4 cm 2 or more

Exclusion criteria

* Patients with superficial or partial thickness skin defect * osteomyelitis patient * An undermining wound, tunneling wound, which can not measure the exact depth, can be used if the wound is open wound due to debridement of wound. * Patients who exceeded 12% of HbA1c within 3 months before participating in the study * Patients with serum creatinine concentration of 3.0 mg / dL or more within 30 days before the study * Patients who have applied other medical devices and growth factors for wound healing within 30 days before participating in the study * Patients with lesion infections (available after infection treatment)

Design outcomes

Primary

MeasureTime frameDescription
wound reduction rate12 weeksAt 12 weeks after the application of the medical device, the wound reduction At 12 weeks after the application of the medical device, the wound reduction rate

Secondary

MeasureTime frameDescription
Complete healing rate12 weeksComplete healing rate after 12 weeks of medical device application \* Definition of complete healing: A complete healing is defined as a state in which the skin is completely reepithelialized and the skin is completely closed. Additional operations such as skin grafting, flap surgery, primary suture, etc. are not performed. (definition of complete healing:
Period of time to complete healingThe period to complete healing(through study completion, an average of 12 weeks)Period of time from medical device application to complete healing \* Definition of complete healing: A complete healing is defined as a state in which the skin is completely reepithelialized and the skin is completely closed. Additional operations such as skin grafting, flap surgery, primary suture, etc. are not performed.
Step of granulation tissue12 weeksStep for 12weeks of granulation tissue (The steps of granulation tissues are visualized by the following criteria, and the steps are recorded separately from A-E) * A: Skin intact or partial thickness wound * B: Bright, beefy red; 75% to 100% of wound filled & or tissue overgrowth * C: right, beefy red; \< 75% & \> 25% of wound filled * D: Pink, &/or dull, dusky red & or fills ≤ 25% of wound * E: No granulation tissue present
The time it took to reach granulation tissue formationThe period of time required for granulation tissue formation to reach 100% (through study completion, an average of 12 weeks)The period of time required for granulation tissue formation to reach 100%
Level of tissue exposed after 12 weeks of medical device application12 weeksAfter 12 weeks of medical device application, the level of exposed tissue is divided into partial thickness skin, full thickness skin, subcutaneous, deep fascia, muscle, tendon, bone, and joint, and the distribution is compared.

Countries

South Korea

Contacts

Primary ContactSang Wha Kim, Ph.D
sw1215@snu.ac.kr82-2-2072-2374

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026